Doughnut holes and price controls

被引:4
作者
Anderson, GF [1 ]
Shea, DG
Hussey, PS
Keyhani, S
Zephyrin, L
机构
[1] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA
[2] Penn State Univ, University Pk, PA 16802 USA
关键词
D O I
10.1377/hlthaff.W4.396
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
In 2003 citizens of Canada, the United Kingdom, and France paid an average of 34-59 percent of what Americans paid for a similar market basket of pharmaceuticals. If the Medicare program were to pay comparable prices for pharmaceuticals, it would be possible to eliminate the "doughnut hole" in its prescription drug benefit and keep Medicare drug spending within the overall limits established by Congress. This provides Congress with a clear choice: reduce the level of cost sharing and improve beneficiaries' access to pharmaceuticals, or allow the pharmaceutical industry to use the higher prices to fund research and development and to engage in other activities.
引用
收藏
页码:W396 / W404
页数:9
相关论文
共 22 条
[1]  
[Anonymous], FEDERAL POLICIES AFF
[2]  
*CMS, 2004, OV MED PRESCR DRUG D
[3]  
DANZON PM, 2003, HLTH AFFAIRS 1029
[4]   The price of innovation: new estimates of drug development costs [J].
DiMasi, JA ;
Hansen, RW ;
Grabowski, HG .
JOURNAL OF HEALTH ECONOMICS, 2003, 22 (02) :151-185
[5]  
Feldstein P., 2003, HLTH POLICY ISSUES E
[6]  
*HILT MOOR ASS, 2002, PHARM IND SEGM PROF
[7]  
*HJ KAIS FAM FDN, 2003, PRESCR DRUG COV MED
[8]   Out-of-pocket medical spending for care of chronic conditions [J].
Hwang, W ;
Weller, W ;
Ireys, H ;
Anderson, G .
HEALTH AFFAIRS, 2001, 20 (06) :267-278
[9]   How much should Medicare pay for drugs? [J].
Newhouse, JP .
HEALTH AFFAIRS, 2004, 23 (01) :89-102
[10]  
*NIH CAR MAN, 2002, CHANG PATT PHARM INN